These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26811629)

  • 1. Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview.
    Frick VO; Rubie C; Keilholz U; Ghadjar P
    World J Gastroenterol; 2016 Jan; 22(2):833-41. PubMed ID: 26811629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly-metastatic colorectal cancer cell released miR-181a-5p-rich extracellular vesicles promote liver metastasis by activating hepatic stellate cells and remodelling the tumour microenvironment.
    Zhao S; Mi Y; Zheng B; Wei P; Gu Y; Zhang Z; Xu Y; Cai S; Li X; Li D
    J Extracell Vesicles; 2022 Jan; 11(1):e12186. PubMed ID: 35041299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL/RANK signaling recruits Tregs via the CCL20-CCR6 pathway and promotes stemness and metastasis in colorectal cancer.
    Ouyang J; Hu S; Zhu Q; Li C; Kang T; Xie W; Wang Y; Li Y; Lu Y; Qi J; Xia M; Chen J; Yang Y; Sun Y; Gao T; Ye L; Liang Q; Pan Y; Zhu C
    Cell Death Dis; 2024 Jun; 15(6):437. PubMed ID: 38902257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokine CCL20 promotes the paclitaxel resistance of CD44
    Chen M; Su J; Feng C; Liu Y; Zhao L; Tian Y
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMAD4 Suppresses Colitis-associated Carcinoma Through Inhibition of CCL20/CCR6-mediated Inflammation.
    Hanna DN; Smith PM; Novitskiy SV; Washington MK; Zi J; Weaver CJ; Hamaamen JA; Lewis KB; Zhu J; Yang J; Liu Q; Beauchamp RD; Means AL
    Gastroenterology; 2022 Nov; 163(5):1334-1350.e14. PubMed ID: 35863523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6
    Li W; Crouse KK; Alley J; Frisbie RK; Fish SC; Andreyeva TA; Reed LA; Thorn M; DiMaggio G; Donovan CB; Bennett D; Garren J; Oziolor E; Qian J; Newman L; Vargas AP; Kumpf SW; Steyn SJ; Schnute ME; Thorarensen A; Hegen M; Stevens E; Collinge M; Lanz TA; Vincent F; Vincent MS; Berstein G
    J Pharmacol Exp Ther; 2023 Jul; 386(1):80-92. PubMed ID: 37142443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma.
    Liu JY; Li F; Wang LP; Chen XF; Wang D; Cao L; Ping Y; Zhao S; Li B; Thorne SH; Zhang B; Kalinski P; Zhang Y
    Br J Cancer; 2015 Sep; 113(5):747-55. PubMed ID: 26284335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment.
    Liu Y; Wei D; Deguchi Y; Xu W; Tian R; Liu F; Xu M; Mao F; Li D; Chen W; Valentin LA; Deguchi E; Yao JC; Shureiqi I; Zuo X
    Gastric Cancer; 2023 Nov; 26(6):904-917. PubMed ID: 37572185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling.
    Xie T; Fu DJ; Li ZM; Lv DJ; Song XL; Yu YZ; Wang C; Li KJ; Zhai B; Wu J; Feng NH; Zhao SC
    Mol Cancer; 2022 Sep; 21(1):173. PubMed ID: 36045408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR6 as a possible therapeutic target in psoriasis.
    Hedrick MN; Lonsdorf AS; Hwang ST; Farber JM
    Expert Opin Ther Targets; 2010 Sep; 14(9):911-22. PubMed ID: 20629596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL20 inhibition for treating inflammation in ankylosing spondylitis.
    Won EJ; Kim HJ; Lee YJ; Kim MJ; Lee HI; Jang HH; Kim SH; Kang JH; Park KJ; Shim SC; Jo S; Kim TH; Kim TJ
    Rheumatology (Oxford); 2023 Dec; 62(12):4000-4005. PubMed ID: 37279731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TH1L involvement in colorectal cancer pathogenesis by regulation of CCL20 through the NF-κB signalling pathway.
    Wang S; Sun Y; Li C; Chong Y; Ai M; Wang Y; Shi H; Shang Y
    J Cell Mol Med; 2024 May; 28(10):e18391. PubMed ID: 38809918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of atherogenesis by chemokine receptor CCR6.
    Wan W; Murphy PM
    Trends Cardiovasc Med; 2011 Jul; 21(5):140-4. PubMed ID: 22732549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
    Trivedi PJ; Adams DH
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S641-S652. PubMed ID: 30137309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes.
    Lee SM; Yang H; Tartar DM; Gao B; Luo X; Ye SQ; Zaghouani H; Fang D
    Diabetologia; 2011 May; 54(5):1136-46. PubMed ID: 21340626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases.
    Gómez-Melero S; Caballero-Villarraso J
    Antibodies (Basel); 2023 Apr; 12(2):. PubMed ID: 37092451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR6
    Anderson LS; Yu S; Rivara KR; Reynolds MB; Hernandez AA; Wu X; Yang HY; Isseroff RR; Miller LS; Hwang ST; Simon SI
    J Invest Dermatol; 2019 Sep; 139(9):2061-2064.e2. PubMed ID: 30935975
    [No Abstract]   [Full Text] [Related]  

  • 18. Many Roles of CCL20: Emphasis on Breast Cancer.
    Osuala KO; Sloane BF
    Postdoc J; 2014 Mar; 2(3):7-16. PubMed ID: 27631019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglia-derived CCL20 deteriorates neurogenesis following intraventricular hemorrhage.
    Yao N; Li Y; Han J; Wu S; Liu X; Wang Q; Li Z; Shi FD
    Exp Neurol; 2023 Dec; 370():114561. PubMed ID: 37802382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases.
    Meyer EA; Croxford AL; Gnerre C; Kulig P; Murphy MJ; Jacob EM; Schäfer G; Richard-Bildstein S; Aissaoui H; Bouis P; Ertel EA; de Kanter R; Keller MP; Lüthi U; Caroff E
    J Med Chem; 2024 May; 67(10):8077-8098. PubMed ID: 38727100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.